Fig. 2: Distribution of response to treatment stratified by receipt of anti-HER2 therapy. | npj Breast Cancer

Fig. 2: Distribution of response to treatment stratified by receipt of anti-HER2 therapy.

From: Enhancing HER2-low breast cancer detection with quantitative transcriptomics

Fig. 2

The proportion of NACT samples in each treatment response category (RCB), split by ERBB2-expression class (a) and HER2 IHC score (b). The left-hand side displays samples from patients that received chemotherapy and the right-hand side displays samples from patients that received combined therapy. Gray color represents pCR, and blue indicates residual disease (non-pCR). Labels denote the absolute number of samples in each bar segment. RCB: residual cancer burden; class: ERBB2-expression class; HER2 IHC: HER2 status determined by immunohistochemistry.

Back to article page